

Dick Menzies

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/7947742/publications.pdf](https://exaly.com/author-pdf/7947742/publications.pdf)

Version: 2024-02-01

195
papers

18,290
citations

18341

62
h-index

14394

129
g-index

237
all docs

237
docs citations

237
times ranked

18222
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustainability and impact of an intervention to improve initiation of tuberculosis preventive treatment: results from a follow-up study of the ACT4 randomized trial. <i>EClinicalMedicine</i> , 2024, 71, 102546.	7.2	0
2	High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2). <i>PLoS ONE</i> , 2023, 18, e0278087.	2.5	3
3	Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 59, 101979.	7.2	9
4	Chapitre 4: Le diagnostic de l'infection tuberculeuse. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2023, 7, 323-341.	0.6	0
5	Effectiveness of germicidal ultraviolet light to inactivate coronaviruses on personal protective equipment to reduce nosocomial transmission. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 886-891.	2.0	5
6	Four months of rifampicin monotherapy for latent tuberculosis infection in children. <i>Clinical and Experimental Pediatrics</i> , 2022, 65, 214-221.	1.9	6
7	Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100166.	3.1	5
8	Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 111-121.	1.7	11
9	Chapter 5: Treatment of tuberculosis disease. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 66-76.	0.6	4
10	Chapter 4: Diagnosis of tuberculosis infection. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 49-65.	0.6	3
11	Chapter 8: Drug-resistant tuberculosis. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 109-128.	0.6	5
12	Chapter 6: Tuberculosis preventive treatment in adults. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 77-86.	0.6	2
13	Safety of prolonged treatment with bedaquiline in programmatic conditions. <i>ERJ Open Research</i> , 2022, 8, 00685-2021.	2.7	7
14	Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patient data meta-analysis. <i>Statistical Methods in Medical Research</i> , 2022, 31, 689-705.	1.6	5
15	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, 2201-2210.	5.7	7
16	Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in Montreal, Canada: a prospective observational and cost-assessment study. <i>CMAJ Open</i> , 2022, 10, E409-E419.	2.5	2
17	Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace. <i>JAMA Network Open</i> , 2022, 5, e2210559.	6.0	19
18	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1042-1051.	8.9	35

#	ARTICLE	IF	CITATIONS
19	Canadian Tuberculosis Standards 8th edition: What's new? And what's next?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 333-336.	0.6	3
20	Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016. Clinical Infectious Diseases, 2021, 73, e3929-e3936.	5.7	26
21	Safety and Efficacy of Rifampin or Isoniazid Among People With <i>Mycobacterium tuberculosis</i> Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2021, 73, e3545-e3554.	5.7	22
22	Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e1116-e1125.	5.7	35
23	Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementation. BMC Public Health, 2021, 21, 177.	3.0	2
24	Build back better: Advances in tuberculosis research in Canada & globally in 2020. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 121-124.	0.6	0
25	The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs. Annals of Internal Medicine, 2021, 174, 501-510.	10.2	165
26	Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health, The, 2021, 6, e272-e282.	10.1	20
27	Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study. BMC Infectious Diseases, 2021, 21, 449.	3.0	3
28	Tuberculosis active case-finding: looking for cases in all the right places?. Lancet Public Health, The, 2021, 6, e261-e262.	10.1	6
29	The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003703.	8.4	25
30	Tuberculosis preventive treatment in people living with HIV- Is the glass half empty or half full?. PLoS Medicine, 2021, 18, e1003702.	8.4	4
31	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 713-722.	6.6	24
32	Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003712.	8.4	21
33	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Medicine, 2021, 18, e1003738.	8.4	21
34	Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2021, 21, e303-e317.	8.9	26
35	Reply to van Deun and Decroo. Clinical Infectious Diseases, 2021, 72, e1168-e1169.	5.7	1
36	Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis. BMC Medical Research Methodology, 2021, 21, 257.	3.2	7

#	ARTICLE	IF	CITATIONS
37	What makes a score a winner?. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 10-11.	8.9	0
38	Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 318-329.	8.9	40
39	Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2020, 55, 1901467.	7.5	60
40	Estimating treatment importance in multidrug-resistant tuberculosis using Targeted Learning: An observational individual patient data network meta-analysis. <i>Biometrics</i> , 2020, 76, 1007-1016.	1.5	9
41	Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. <i>The Lancet Digital Health</i> , 2020, 2, e573-e581.	11.3	86
42	Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective. <i>Canadian Journal of Public Health</i> , 2020, 111, 939-944.	2.5	3
43	Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. <i>Annals of Internal Medicine</i> , 2020, 173, 169-178.	10.2	21
44	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. <i>Lancet, The</i> , 2020, 396, 402-411.	12.1	50
45	Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. <i>Cmaj</i> , 2020, 192, E1146-E1155.	4.1	30
46	Solutions to improve the latent tuberculosis Cascade of Care in Ghana: a longitudinal impact assessment. <i>BMC Infectious Diseases</i> , 2020, 20, 352.	3.0	10
47	Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e033945.	2.1	33
48	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 383-394.	10.4	171
49	Advances in tuberculosis in 2019 in Canada and globally. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, S34-S37.	0.6	0
50	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>American Journal of Transplantation</i> , 2020, 20, 1196-1206.	4.9	39
51	Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2020, 26, .	4.4	10
52	Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 370, m2516.	7.8	702
53	Changes in treatment for multidrug-resistant tuberculosis according to national income. <i>European Respiratory Journal</i> , 2020, 56, 2001394.	7.5	4
54	Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. <i>European Respiratory Journal</i> , 2020, 55, 1902048.	7.5	33

#	ARTICLE	IF	CITATIONS
55	Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 368, m549.	7.8	65
56	Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0241536.	2.5	261
57	Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-11.	63.1	290
58	DÃ©pistage actif chez les groupes courant un risque accru de contracter le SRAS-CoV-2 au Canada : coÃ»ts et ressources humaines nÃ©cessaires. <i>Cmaj</i> , 2020, 192, E1734-E1746.	4.1	0
59	Multidrug-resistant tuberculosis â€œ Authors' reply. <i>Lancet, The</i> , 2019, 394, 299-300.	12.1	2
60	Knowledge, attitudes and practices on tuberculosis transmission and prevention among auxiliary healthcare professionals in three Brazilian high-burden cities: a cross-sectional survey. <i>BMC Health Services Research</i> , 2019, 19, 532.	2.2	19
61	Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. <i>Social Science and Medicine</i> , 2019, 240, 112578.	4.0	17
62	A systematic review of the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest x-rays for pulmonary tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0221339.	2.5	123
63	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	10.4	97
64	The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study. <i>PLoS ONE</i> , 2019, 14, e0211355.	2.5	9
65	The mTST â€œ An mHealth approach for training and quality assurance of tuberculin skin test administration and reading. <i>PLoS ONE</i> , 2019, 14, e0215240.	2.5	10
66	Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial. <i>BMJ Open</i> , 2019, 9, e025831.	2.1	19
67	Is there a fundamental flaw in Canadaâ€™s post-arrival immigrant surveillance system for tuberculosis?. <i>PLoS ONE</i> , 2019, 14, e0212706.	2.5	13
68	Latent tuberculosis infection in healthcare workers in low- and middle-income countries: an updated systematic review. <i>European Respiratory Journal</i> , 2019, 53, 1801789.	7.5	54
69	Intestinal dysbiosis compromises alveolar macrophage immunity to <i>Mycobacterium tuberculosis</i> . <i>Mucosal Immunology</i> , 2019, 12, 772-783.	6.1	68
70	No evidence of increased risk of acquired rifampin resistance. <i>Cmaj</i> , 2019, 191, E1314-E1315.	4.1	1
71	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	6.6	300
72	Asthma phenotypes based on health services use for allergic diseases in a province-wide birth cohort. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 50-57.e2.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. <i>Thorax</i> , 2019, 74, 291-297.	7.2	43
74	Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3534-3549.	1.6	14
75	Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review. <i>European Respiratory Journal</i> , 2019, 53, 1801030.	7.5	39
76	What's Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 229-230.	3.5	2
77	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	10.4	83
78	Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study. <i>Lancet Public Health</i> , 2018, 3, e133-e142.	10.1	25
79	New short regimens for latent tuberculosis treatment: safety first!. <i>European Respiratory Journal</i> , 2018, 52, 1802180.	7.5	5
80	Using a quality improvement approach to improve care for latent tuberculosis infection. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 737-747.	4.5	7
81	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet</i> , 2018, 392, 821-834.	12.1	473
82	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. <i>New England Journal of Medicine</i> , 2018, 379, 440-453.	30.1	284
83	Safety and Side Effects of Rifampin versus Isoniazid in Children. <i>New England Journal of Medicine</i> , 2018, 379, 454-463.	30.1	131
84	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	8.4	101
85	Knowledge and perceptions of tuberculosis transmission and prevention among physicians and nurses in three Brazilian capitals with high incidence of tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 168-170.	0.8	9
86	Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw838.	5.7	75
87	Finding the right dose of rifampicin, and the right dose of optimism. <i>Lancet Infectious Diseases</i> , 2017, 17, 2-3.	8.9	5
88	Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. <i>Lancet Public Health</i> , 2017, 2, e47-e55.	10.1	37
89	Isoniazid-resistant tuberculosis treatment with first-line drugs—Author reply. <i>Lancet Infectious Diseases</i> , 2017, 17, 260.	8.9	0
90	Association Between Bacillus Calmette-Guérin Vaccination and Childhood Asthma in the Quebec Birth Cohort on Immunity and Health. <i>American Journal of Epidemiology</i> , 2017, 186, 344-355.	3.7	15

#	ARTICLE	IF	CITATIONS
91	An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1600803.	7.5	89
92	Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1211-1220.	5.7	25
93	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2017, 49, 1600993.	7.5	21
94	Effectiveness of Canada's tuberculosis surveillance strategy in identifying immigrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e450-e457.	10.1	25
95	<i>Bacillus Calmette-Guérin (BCG) vaccination patterns in the province of Québec, Canada, 1956–1974. Vaccine</i> , 2017, 35, 4777-4784.	4.0	10
96	Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. <i>European Respiratory Journal</i> , 2017, 50, 1700061.	7.5	86
97	Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 223-234.	8.9	205
98	Knowledge about tuberculosis transmission and prevention and perceptions of health service utilization among index cases and contacts in Brazil: Understanding losses in the latent tuberculosis cascade of care. <i>PLoS ONE</i> , 2017, 12, e0184061.	2.5	21
99	Reply to Dobler. <i>Clinical Infectious Diseases</i> , 2017, 65, 1423-1424.	5.7	0
100	The impact of the Brazilian family health on selected primary care sensitive conditions: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0182336.	2.5	86
101	Tuberculosis transmission in the Indigenous peoples of the Canadian prairies. <i>PLoS ONE</i> , 2017, 12, e0188189.	2.5	7
102	Current Options in Treatment and Issues in Tuberculosis Care in Low- and Middle-Income Countries. , 2017, , 99-116.		0
103	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0151724.	2.5	12
104	Housing and tuberculosis in an Inuit village in northern Quebec: a case-control study. <i>CMAJ Open</i> , 2016, 4, E496-E506.	2.5	16
105	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	7.5	28
106	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1269-1278.	8.9	348
107	Treatment of human disease due to <i>Mycobacterium bovis</i> : a systematic review. <i>European Respiratory Journal</i> , 2016, 48, 1500-1503.	7.5	24
108	Putting numbers on the End TB Strategy—“an impossible dream?”. <i>The Lancet Global Health</i> , 2016, 4, e764-e765.	6.3	3

#	ARTICLE	IF	CITATIONS
109	Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2016, 16, 679.	3.0	13
110	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 887-895.	5.7	66
111	Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population. <i>BMC Infectious Diseases</i> , 2015, 15, 381.	3.0	11
112	Reemergence and Amplification of Tuberculosis in the Canadian Arctic. <i>Journal of Infectious Diseases</i> , 2015, 211, 1905-1914.	3.9	80
113	Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs. <i>BMC Public Health</i> , 2015, 15, 141.	3.0	11
114	Reply to Wang and Zhang. <i>Clinical Infectious Diseases</i> , 2015, 60, 1286-1287.	5.7	0
115	Inadequate Diet is Associated with Acquiring <i>Mycobacterium tuberculosis</i> Infection in an Inuit Community: A Case-Control Study. <i>Annals of the American Thoracic Society</i> , 2015, 12, 150622133645008.	3.6	21
116	The impact of tuberculosis on health utility: a longitudinal cohort study. <i>Quality of Life Research</i> , 2015, 24, 1337-1349.	3.2	13
117	Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 229-237.	6.6	29
118	Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2015, 3, 451-461.	10.4	253
119	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	7.5	492
120	Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. <i>European Respiratory Journal</i> , 2015, 46, 1461-1470.	7.5	40
121	Population genomics of <i>Mycobacterium tuberculosis</i> in the Inuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13609-13614.	7.6	81
122	Health-related quality of life and tuberculosis: a longitudinal cohort study. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 65.	2.4	42
123	Drug-Resistant Tuberculosis. , 2014, , 1-20.		0
124	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.7	119
125	Looking for TB in the sky: Money well spent?. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 3-4.	3.2	0
126	Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. <i>European Respiratory Journal</i> , 2014, 43, 566-581.	7.5	19

#	ARTICLE	IF	CITATIONS
127	A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. <i>Infectious Diseases and Therapy</i> , 2013, 2, 123-144.	4.1	95
128	Molecular methods for tuberculosis trials: time for whole-genome sequencing?. <i>Lancet Respiratory Medicine</i> , 2013, 1, 759-761.	10.4	4
129	Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. <i>Journal of Epidemiology and Global Health</i> , 2013, 3, 105.	3.0	14
130	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	7.5	228
131	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	7.5	349
132	How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI. <i>PLoS ONE</i> , 2013, 8, e56044.	2.5	23
133	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. <i>PLoS ONE</i> , 2013, 8, e54748.	2.5	63
134	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	432
135	An Updated Systematic Review and Meta-analysis on the Treatment of Active Tuberculosis in Patients With HIV Infection. <i>Clinical Infectious Diseases</i> , 2012, 55, 1154-1163.	5.7	72
136	Predictive value of interferon- γ release assays for incident active tuberculosis: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2012, 12, 45-55.	8.9	449
137	TB Screening in Canadian Health Care Workers Using Interferon-Gamma Release Assays. <i>PLoS ONE</i> , 2012, 7, e43014.	2.5	30
138	Treatment of latent TB: first do no harm. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 491-493.	4.5	6
139	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. <i>New England Journal of Medicine</i> , 2011, 365, 2155-2166.	30.1	788
140	Developing a Tuberculosis Transmission Model That Accounts for Changes in Population Health. <i>Medical Decision Making</i> , 2011, 31, 53-68.	2.7	10
141	Fatores associados ao atraso no diagnóstico da tuberculose pulmonar no estado do Rio de Janeiro. <i>Jornal Brasileiro De Pneumologia</i> , 2011, 37, 512-520.	0.8	50
142	Treatment of drug-resistant tuberculosis. <i>Infection and Drug Resistance</i> , 2011, 4, 129.	2.8	30
143	Therapeutic Drug Monitoring in the Treatment of Active Tuberculosis. <i>Canadian Respiratory Journal</i> , 2011, 18, 225-229.	1.7	62
144	Reduced Transmissibility of East African Indian Strains of <i>Mycobacterium tuberculosis</i> . <i>PLoS ONE</i> , 2011, 6, e25075.	2.5	63

#	ARTICLE	IF	CITATIONS
145	Tuberculosis: evidence review for newly arriving immigrants and refugees. <i>Cmaj</i> , 2011, 183, E939-E951.	4.1	90
146	Adverse events associated with treatment of latent tuberculosis in the general population. <i>Cmaj</i> , 2011, 183, E173-E179.	4.1	51
147	The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. <i>PLoS Medicine</i> , 2011, 8, e1001012.	8.4	494
148	Occupational respiratory infections. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.7	12
149	Treatment of latent tuberculosis infection: An update. <i>Respirology</i> , 2010, 15, 603-622.	2.9	170
150	Saudi guidelines for testing and treatment of latent tuberculosis infection. <i>Annals of Saudi Medicine</i> , 2010, 30, 38.	1.3	40
151	Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. <i>Thorax</i> , 2010, 65, 582-587.	7.2	48
152	Treatment of Active Tuberculosis in HIV-coinfected Patients: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2010, 50, 1288-1299.	5.7	158
153	Occupation-Related Respiratory Infections Revisited. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 655-680.	4.2	5
154	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. <i>Lancet, The</i> , 2010, 375, 1920-1937.	12.1	408
155	Patients' Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil. <i>PLoS ONE</i> , 2010, 5, e14014.	2.5	72
156	Saudi guidelines for testing and treatment of latent tuberculosis infection. <i>Annals of Saudi Medicine</i> , 2010, 30, 38-49.	1.3	2
157	Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2009, 6, e1000150.	8.4	160
158	Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000146.	8.4	171
159	Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 273-280.	6.6	249
160	Tuberculosis screening of travelers to higher-incidence countries: A cost-effectiveness analysis. <i>BMC Public Health</i> , 2008, 8, 201.	3.0	15
161	Influence of Multidrug Resistance on Tuberculosis Treatment Outcomes with Standardized Regimens. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 306-312.	6.6	67
162	Predicting Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1055-1057.	6.6	20

#	ARTICLE	IF	CITATIONS
163	Challenges to Tuberculin Screening and Follow-up in an Urban Aboriginal Sample in Montreal, Canada. <i>Journal of Health Care for the Poor and Underserved</i> , 2008, 19, 369-379.	0.8	6
164	Systematic Review: T-Cell ⁺ -based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update. <i>Annals of Internal Medicine</i> , 2008, 149, 177.	10.2	1,131
165	Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection. <i>Annals of Internal Medicine</i> , 2008, 149, 689.	10.2	182
166	Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2008, 149, 123.	10.2	155
167	T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data. <i>PLoS ONE</i> , 2008, 3, e1850.	2.5	89
168	Costs for Tuberculosis Care in Canada. <i>Canadian Journal of Public Health</i> , 2008, 99, 391-396.	2.5	28
169	Insect evidence for environmental and climate changes from Younger Dryas to Sub-Boreal in a river floodplain at St-Momelin (St-Omer basin, northern France), Coleoptera and Trichoptera. <i>Palaeogeography, Palaeoclimatology, Palaeoecology</i> , 2007, 245, 483-504.	2.3	22
170	Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. <i>Annals of Internal Medicine</i> , 2007, 146, 340.	10.2	878
171	Adverse reactions to first-line antituberculosis drugs. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 231-249.	2.5	266
172	The Long-term Health and Economic Benefits of DOTS Implementation in Ecuador. <i>Canadian Journal of Public Health</i> , 2006, 97, 14-19.	2.5	4
173	Dwellings, crowding, and tuberculosis in Montreal. <i>Social Science and Medicine</i> , 2006, 63, 501-511.	4.0	49
174	Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. <i>BMC Public Health</i> , 2006, 6, 209.	3.0	25
175	Serial Testing of Health Care Workers for Tuberculosis Using Interferon- γ Assay. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 349-355.	6.6	257
176	Tuberculosis among Health-Care Workers in Low- and Middle-Income Countries: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e494.	8.4	430
177	Building-Related Illnesses. , 2006, , 737-783.		4
178	Microbial Contamination in Airplane Cabins: Health Effects and Remediation. <i>The Handbook of Environmental Chemistry Volume 4</i> , 2005, , 151-167.	0.0	2
179	Domestic Returns from Investment in the Control of Tuberculosis in Other Countries. <i>New England Journal of Medicine</i> , 2005, 353, 1008-1020.	30.1	139
180	Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 445-449.	6.6	156

#	ARTICLE	IF	CITATIONS
181	Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 1472-1477.	6.6	693
182	Efficacy of Environmental Measures in Reducing Potentially Infectious Bioaerosols During Sputum Induction. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 483-489.	2.0	19
183	Effect of ultraviolet germicidal lights installed in office ventilation systems on workers' health and wellbeing: double-blind multiple crossover trial. <i>Lancet, The</i> , 2003, 362, 1785-1791.	12.1	112
184	Factors Associated with Tuberculin Conversion in Canadian Microbiology and Pathology Workers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 599-602.	6.6	26
185	Delay in Diagnosis among Hospitalized Patients with Active Tuberculosis—Predictors and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 927-933.	6.6	172
186	Capital Budgeting Evaluation Practices of Building Contractors in Hong Kong. <i>Construction Economics and Building</i> , 2002, 2, 81-93.	1.0	5
187	Hospital Ventilation and Risk for Tuberculous Infection in Canadian Health Care Workers. <i>Annals of Internal Medicine</i> , 2000, 133, 779.	10.2	170
188	Comparison of Cost-Effectiveness of Tuberculosis Screening of Close Contacts and Foreign-Born Populations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 2079-2086.	6.6	122
189	Tuberculosis Screening of Immigrants to Low-Prevalence Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, 780-789.	6.6	100
190	Aeroallergens and work-related respiratory symptoms among office workers. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 38-44.	2.9	53
191	Impact of Immigration on Tuberculosis Infection Among Canadian-born Schoolchildren and Young Adults in Montreal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 1915-1921.	6.6	27
192	Building-Related Illnesses. <i>New England Journal of Medicine</i> , 1997, 337, 1524-1531.	30.1	135
193	Effect of a New Ventilation System on Health and Well-Being of Office Workers. <i>Archives of Environmental Health</i> , 1997, 52, 360-367.	0.3	42
194	Issues in the Management of Contacts of Patients with Active Pulmonary Tuberculosis. <i>Canadian Journal of Public Health</i> , 1997, 88, 197-201.	2.5	30
195	Tuberculosis among Health Care Workers. <i>New England Journal of Medicine</i> , 1995, 332, 92-98.	30.1	331